Recombinant IFN beta does not prevent the development of permanent physical disability in SPMS. We were unable to verify the effect on cognitive function for the lack of comparable data. This treatment significantly reduces the risk of relapse and of short -term relapse-related disability.
Jan 18, 2012
Conclusion: 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of ...
Conclusion 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of IFNβ ...
People also ask
What is the new treatment for secondary progressive MS?
Does interferon beta help with MS?
What is the FDA approved treatment for secondary progressive MS?
How many MS patients respond to interferon beta treatment?
The pooled analysis showed an overall risk reduction by about 20% in patients treated with 8 MIU (250 mcg) IFNB-1b for EDSS progression confirmed at 6 months (p ...
Missing: systematic | Show results with:systematic
The pooled analysis showed an overall risk reduction by about 20% in patients treated with 8 MIU (250 mcg) IFNB-1b for EDSS progression confirmed at 6 months (p ...
Missing: systematic | Show results with:systematic
The aim was to determine whether IFNβ can reduce the risk of disability and cognitive impairment progression in SPMS. Using Cochrane methodology, we reviewed ...
The aim was to determine whether IFNβ can reduce the risk of disability and cognitive impairment progression in SPMS. Methods: Using Cochrane methodology, we ...
In summary, interferon-β is effective in reducing relapses in SPMS, and may have a very modest effect in slowing disability progression, mainly in early SPMS ...
Mar 14, 2007 · Over the total study period, 62.2% of patients had confirmed progression. The analysis of the time to con- firmed progression showed that ...
Missing: systematic review
This non-systematic review identified four randomised trials that have tested the efficacy of interferon beta in secondary progressive multiple sclerosis ...